Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Uric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.46 |
| ▸ | TYMP known ✓ | P19971 | 10/20 | 0.39 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.38 |
| ▸ | PNP known ✓ | P00491 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uric Acid SCHEMBL1331321 | 0.97 | GDA (1.00) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL3417988 | 0.97 | GDA (1.00) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL22069923 | 0.97 | GDA (1.00) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL7933 | 0.97 | GDA (1.00) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL11473111 | 0.95 | GDA (0.84) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL7020961 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL921153 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL447964 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL8951222 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD | |
| Uric Acid SCHEMBL1071965 | 0.94 | GDA (0.94) | GDAALDH1A1CYP1A2CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719419-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CDK4 INHIBITORS | Pfizer Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246825-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CDK4 INHIBITORS | PFIZER INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-110249219-B | Risk factor monitoring | 安晟信医疗科技控股公司 | 2022-08-23 | — | — | CN | disclosed |
| US-11353417-B2 | Risk factor monitoring | ASCENSIA DIABETES CARE HOLDINGS AG (CH) | 2022-06-07 | — | — | US | disclosed |
| CN-113509464-A | Intestinal luminal uric acid adsorbent and application and preparation method thereof | 华侨大学 | 2021-10-19 | — | — | CN | disclosed |
| US-8088899-B2 | Human granulocyte-colony stimulating factor isoforms | CJ CHEILJEDANG CORPORATION (KR) | 2012-01-03 | — | — | US | disclosed |
| US-20100143288-A1 | HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR ISOFORMS | CJ CHEILJEDANG CORPORATION (KR) | 2010-06-10 | — | — | US | disclosed |
| EP-1885185-A2 | CELLULAR CARDIOMYOPLASTY AS SUPPORTIVE THERAPY IN PATIENTS WITH HEART DISEASE | Mytogen, Inc. (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006122005-A2 | CELLULAR CARDIOMYOPLASTY AS SUPPORTIVE THERAPY IN PATIENTS WITH HEART DISEASE | MYTOGEN, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-0713136-B1 | A method for processing silver halide photographic material with a specific fixing solution | KONISHIROKU PHOTO IND (JP) | 1999-01-20 | — | — | EP | disclosed |